Five randomised controlled trials of adjuvant treatment in patients with histologically proven pancreatic ductal adenocarcinoma were identified, of which the four most recent trials provided individual patient data (875 patients).
Over 30 patients have been treated worldwide using the current protocols, and recent trials provided the demonstration of long-term clinical efficacy of HSC gene therapy for SCID-ADA in combination with gene and cell therapy.
Nevertheless, the findings, like those of a recent trial, provide no firm support that this association reflects a causal protective effect [ 27].
In support of our hypothesis, a recent trial provided initial evidence that a supervised exercise programme commencing two months after TKR resulted in improved function and reduced pain compared to a home exercise programme [ 35].
While recent clinical trials provide strong evidence that enhancing SERCA2a expression can alleviate impairment of cardiac function [ 48– 50], it remains unclear whether SERCA2a deficiency can itself precipitate decompensation and heart failure.
Results from two recent large-scale trials provide support for the view that the presence of 1p 19q deletion identifies a subgroup with better clinical outcome [ 1, 41].
This paper describes the ExpertLens system and methodology, briefly discusses recent ExpertLens trials, provides conceptual arguments for why it is an appropriate model for eliciting expert opinions, illustrates its main components and analytics by using an infrastructure investment example, and discusses a research agenda for testing the underlying tenets of the ExpertLens approach.
However, two recent Australian trials provided no evidence of a substantial reduction in the duration of mechanical ventilation or length of stay with the use of protocol-directed sedation compared with usual local management [ 140, 141].
Rather than confirm expected benefits, recent trials instead provide a most unwelcome quantification of the risks of intensive glycemic control, including high treatment costs, increased risk of severe hypoglycemia, substantial weight gain, and even, in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, an increased risk of death (4– 6).
Recent trials have provided differing estimates of the benefits of self-monitoring of blood glucose (SMBG) for non-insulin treated patients with type 2 diabetes.
